| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Guizhou Bailing Group Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.46 |
| 52 Week High | CN¥9.22 |
| 52 Week Low | CN¥6.28 |
| Beta | 0.45 |
| 1 Month Change | -14.66% |
| 3 Month Change | -8.50% |
| 1 Year Change | -20.35% |
| 3 Year Change | -21.22% |
| 5 Year Change | -39.17% |
| Change since IPO | 53.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2424 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.2% | 5.7% | 4.2% |
| 1Y | -20.3% | -11.0% | -13.2% |
Return vs Industry: 002424 underperformed the CN Pharmaceuticals industry which returned -11% over the past year.
Return vs Market: 002424 underperformed the CN Market which returned -13.2% over the past year.
Price Volatility
| 2424 volatility | |
|---|---|
| 2424 Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 002424 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002424's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 6,138 | Min Niu | www.gzbl.com |
Guizhou Bailing Group Pharmaceutical Co., Ltd. research, develops, produces, and sells medicines in China. The company provides medicines in the form of tablets, capsules, granules, syrups, powders, pills, tinctures, sprays, lotions, and cream for cardiovascular and cerebrovascular diseases, cough, cold, pediatric, and gynecologic diseases.
Guizhou Bailing Group Pharmaceutical Co., Ltd. Fundamentals Summary
| 2424 fundamental statistics | |
|---|---|
| Market cap | CN¥8.95b |
| Earnings (TTM) | -CN¥455.12m |
| Revenue (TTM) | CN¥4.50b |
2.0x
P/S Ratio-19.7x
P/E RatioIs 2424 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2424 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.50b |
| Cost of Revenue | CN¥1.95b |
| Gross Profit | CN¥2.55b |
| Other Expenses | CN¥3.01b |
| Earnings | -CN¥455.12m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 56.63% |
| Net Profit Margin | -10.10% |
| Debt/Equity Ratio | 55.2% |
How did 2424 perform over the long term?
See historical performance and comparison